Materiality of Superbugs
Investors are starting to forecast a post-pandemic world. As part of these efforts, it is crucial that they understand and manage the risks of antimicrobial resistance (AMR). If left unchecked, AMR is set to substantially undermine the global economy’s financial recovery and future outlook. Here, Mara Lilley and Sana Johnson run through the main risks and opportunities presented by superbugs for pharma companies and resources available for navigating through them.
The viewpoint covers:
- Why antimicrobial resistance (AMR) is a material issue for investors in pharmaceutical companies.
- The main risks and opportunities presented by superbugs for pharma companies.
- Resources available for investors to navigate through these risks and steer better outcomes.
- How the Access to Medicine Foundation supports investor leadership in the fight against superbugs through the Investor Action on AMR initiative.
The issues were discussed in a virtual event organised by the Investor Action on AMR Initiative, which is jointly coordinated by the Access to Medicine Foundation, the FAIRR Initiative, the UK Department of Health & Social Care, and the Principles for Responsible Investment (PRI). Watch the event here.